---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-213269"
form_type: "8-K"
ticker: "BOLD"
cik: "0001782303"
company_name: "Boundless Bio, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:09:06.984540+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Boundless Bio Q1 2026 net loss $13.6M; cash $92.8M provides runway into H2 2028

## Summary
- Cash, cash equivalents, and short-term investments $92.8M as of March 31, 2026.
- Net loss $13.6M vs $15.8M in Q1 2025; R&D expense $9.7M vs $12.1M.
- KOMODO-1 first-in-human trial of BBI-940 enrolling patients with ER+/HER2- and TNBC-LAR breast cancer.
- AACR 2026 data showed tumor regression from BBI-940 in ecDNA+ TNBC-LAR and ER+ breast cancer models.
- G&A expense $4.7M vs $5.2M year-over-year.

## SEC filing metadata
- accession: 0001193125-26-213269
- form_type: 8-K
- ticker: BOLD
- cik: 0001782303
- company_name: Boundless Bio, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782303/000119312526213269/0001193125-26-213269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782303/000119312526213269/bold-20260508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-213269
- JSON: https://secwatch.observer/filing/0001193125-26-213269.json
- Plain text: https://secwatch.observer/filing/0001193125-26-213269.txt

## Source-grounded claims
- claim_id: 7d675efb05da8ab0dc20399964a3b542f48d955a
  claim: Boundless Bio, Inc. reported the fiscal quarter ended March 31, 2026 results: net income Net loss totaled $13.6 million for the first quarter of 2026.
  evidence_excerpt: Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 8, 2026 – Boundless Bio (Nasdaq: BOLD) , a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782303/000119312526213269/0001193125-26-213269-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.